Catabasis Pharmaceuticals Announces the Initiation of an Open- Label Extension for the MoveDMD ® Trial Studying Edasalonexent (CAT -1004) in Duchenne Muscular Dystrophy
You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.
We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you are agreeing to accept our use of cookies. For more information about cookies please visit our Privacy Policy page.I Agree
